Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elin Aamdal

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Oncoimmunology|December 20, 2024
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survivalRagnhild Reehorst Lereim, Claire Dunn, Elin Aamdal, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 5, 2025
A simple automated assay format for measuring multiple immune checkpoint inhibitorsRagnhild V Nome, Øystein Flatebø, Sigurd Leinæs Bøe, et al.
Journal for Immunotherapy of Cancer|May 25, 2022
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trialsEspen Basmo Ellingsen, Elin Aamdal, Tormod Guren, et al.
Frontiers in Immunology|May 28, 2021
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa TrialElin Aamdal, Else Marit Inderberg, Espen Basmo Ellingsen, et al.
Journal of Translational Medicine|September 11, 2022
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccinationEspen Basmo Ellingsen, Gergana Bounova, Iliana Kerzeli, et al.
International Journal of Cancer|August 27, 2021
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-upElin Aamdal, Kari D Jacobsen, Oddbjørn Straume, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Oncoimmunology|December 20, 2024
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survivalRagnhild Reehorst Lereim, Claire Dunn, Elin Aamdal, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 5, 2025
A simple automated assay format for measuring multiple immune checkpoint inhibitorsRagnhild V Nome, Øystein Flatebø, Sigurd Leinæs Bøe, et al.
Journal for Immunotherapy of Cancer|May 25, 2022
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trialsEspen Basmo Ellingsen, Elin Aamdal, Tormod Guren, et al.
Frontiers in Immunology|May 28, 2021
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa TrialElin Aamdal, Else Marit Inderberg, Espen Basmo Ellingsen, et al.
Journal of Translational Medicine|September 11, 2022
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccinationEspen Basmo Ellingsen, Gergana Bounova, Iliana Kerzeli, et al.
International Journal of Cancer|August 27, 2021
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-upElin Aamdal, Kari D Jacobsen, Oddbjørn Straume, et al.
Pageof 1